With its new digital therapeutics platform, Mind Cure is positioning itself as an emerging leader in the psychedelic drug industry.
Mind Cure has acquired Epiphany360, a digital therapeutics platform for the treatment of mental health conditions.
The Compass Pathways IPO was a huge catalyst for the whole sector. Will a MindMed up-listing have the same impact?
Cybin Corp. announces it has closed on an oversubscribed private placement of CAD$45 million as it prepares to go public.
Acute need. Huge markets. A wide-open playing field. Those are some of the best reasons to invest in psychedelic drug stocks.